Travere Therapeutics (TVTX) Stock Forecast, Price Target & Predictions
TVTX Stock Forecast
Travere Therapeutics stock forecast is as follows: an average price target of $21.60 (represents a 60.24% upside from TVTX’s last price of $13.48) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
TVTX Price Target
The average price target for Travere Therapeutics (TVTX) is $21.60 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $12.00. This represents a potential 60.24% upside from TVTX's last price of $13.48.
TVTX Analyst Ratings
According to 11 Wall Street analysts, Travere Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for TVTX stock is 0 'Strong Buy' (0.00%), 9 'Buy' (81.82%), 2 'Hold' (18.18%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Travere Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 10, 2024 | Ed Nash | Canaccord Genuity | $23.00 | $12.70 | 81.17% | 70.62% |
| Sep 09, 2024 | Vamil Divan | Guggenheim | $25.00 | $12.62 | 98.18% | 85.46% |
| Aug 28, 2024 | Nicole Gabreski | Piper Sandler | $12.00 | $8.96 | 33.93% | -10.98% |
| Aug 02, 2024 | Ed Arce | H.C. Wainwright | $20.00 | $9.24 | 116.45% | 48.37% |
| May 07, 2024 | Ed Nash | Canaccord Genuity | $18.00 | $6.55 | 174.81% | 33.53% |
| Apr 24, 2024 | Ed Arce | H.C. Wainwright | $19.00 | $5.47 | 247.03% | 40.95% |
| Dec 05, 2022 | - | Wells Fargo | $28.00 | $20.08 | 39.44% | 107.72% |
The latest Travere Therapeutics stock forecast, released on Sep 10, 2024 by Ed Nash from Canaccord Genuity, set a price target of $23.00, which represents a 81.17% increase from the stock price at the time of the forecast ($12.70), and a 70.62% increase from TVTX last price ($13.48).
Travere Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 3 | 4 | 6 |
| Avg Price Target | $20.00 | $20.00 | $19.50 |
| Last Closing Price | $13.48 | $13.48 | $13.48 |
| Upside/Downside | 48.37% | 48.37% | 44.66% |
In the current month, the average price target of Travere Therapeutics stock is $20.00, according to 3 Wall Street analysts offering twelve months forecast. The average price target represents a 48.37% increase as opposed to Travere Therapeutics's last price of $13.48. This month's average price target is down 0.00% compared to last quarter, and up 2.56% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 10, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 09, 2024 | Guggenheim | - | Buy | Upgrade |
| Sep 06, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 30, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Aug 28, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 02, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 02, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 02, 2024 | Wedbush | Outperform | Outperform | Hold |
| Aug 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Travere Therapeutics's last stock rating was published by Canaccord Genuity on Sep 10, 2024. The company gave TVTX a "Buy" rating, the same as its previous rate.
Travere Therapeutics Financial Forecast
Travere Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $37.09M | $59.70M | $56.99M | $55.87M | $53.50M | - | $48.49M | $57.25M | $68.22M | $54.62M | $47.41M | $50.98M | $51.14M | $48.43M | $47.77M | $46.69M | $44.37M | $44.71M | $39.57M |
| Avg Forecast | $109.70M | $92.94M | $84.54M | $69.22M | $67.45M | $61.20M | $50.40M | $43.46M | $41.69M | $57.33M | $53.56M | $50.61M | $53.01M | $54.12M | $49.63M | $52.19M | $57.80M | $60.93M | $50.33M | $50.09M | $51.66M | $47.84M | $47.59M | $43.43M | $46.02M | $45.29M | $43.01M | $41.41M |
| High Forecast | $138.77M | $117.57M | $106.94M | $87.56M | $85.32M | $78.73M | $63.75M | $54.98M | $44.27M | $131.96M | $67.75M | $64.02M | $67.06M | $68.46M | $49.63M | $67.37M | $74.61M | $78.66M | $64.97M | $64.65M | $66.69M | $61.75M | $61.43M | $56.06M | $59.41M | $58.46M | $55.51M | $53.45M |
| Low Forecast | $84.34M | $71.46M | $65.00M | $53.22M | $51.86M | $48.35M | $38.75M | $33.42M | $39.31M | $15.17M | $41.18M | $38.91M | $40.76M | $41.61M | $49.63M | $43.45M | $48.12M | $50.73M | $41.90M | $41.70M | $43.01M | $39.83M | $39.62M | $36.16M | $38.32M | $37.71M | $35.81M | $34.47M |
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.65% | 1.11% | 1.13% | 1.05% | 0.99% | - | 0.93% | 0.99% | 1.12% | 1.09% | 0.95% | 0.99% | 1.07% | 1.02% | 1.10% | 1.01% | 0.98% | 1.04% | 0.96% |
Travere Therapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $41.69M, with a low forecast of $39.31M, and a high forecast of $44.27M. TVTX's average Quarter revenue forecast represents a 12.39% increase compared to the company's last Quarter revenue of $37.09M (Sep 23).
Travere Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-89.24M | $-85.69M | $-67.01M | $-65.03M | $-54.86M | - | $-49.65M | $-42.15M | $-8.96M | $-25.98M | $-33.57M | $-17.36M | $-6.24M | $-11.23M | $-7.63M | $-11.11M | $-12.09M | $-25.62M | $-20.14M |
| Avg Forecast | $-73.46M | $-62.24M | $-56.62M | $-46.36M | $-45.17M | $-40.98M | $-33.75M | $-51.39M | $-27.92M | $-38.40M | $-35.87M | $-46.72M | $-35.50M | $-22.78M | $-33.24M | $-42.47M | $-30.93M | $-20.71M | $-30.88M | $-21.40M | $-34.60M | $-32.04M | $-31.87M | $-29.08M | $-30.82M | $-30.33M | $-28.80M | $-27.73M |
| High Forecast | $-56.48M | $-47.85M | $-43.53M | $-35.64M | $-34.73M | $-32.38M | $-25.95M | $-41.11M | $-26.32M | $-10.16M | $-27.58M | $-37.38M | $-27.30M | $-18.23M | $-33.24M | $-33.98M | $-24.75M | $-16.57M | $-24.70M | $-17.12M | $-28.81M | $-26.67M | $-26.53M | $-24.21M | $-25.66M | $-25.25M | $-23.98M | $-23.09M |
| Low Forecast | $-92.93M | $-78.73M | $-71.62M | $-58.64M | $-57.14M | $-52.72M | $-42.69M | $-61.67M | $-29.65M | $-88.37M | $-45.37M | $-56.06M | $-44.91M | $-27.34M | $-33.24M | $-50.97M | $-37.12M | $-24.85M | $-37.06M | $-25.68M | $-44.66M | $-41.35M | $-41.14M | $-37.54M | $-39.78M | $-39.15M | $-37.18M | $-35.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.32% | 2.39% | 1.43% | 1.83% | 2.41% | - | 1.17% | 1.36% | 0.43% | 0.84% | 1.57% | 0.50% | 0.19% | 0.35% | 0.26% | 0.36% | 0.40% | 0.89% | 0.73% |
undefined analysts predict TVTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Travere Therapeutics's previous annual EBITDA (undefined) of $NaN.
Travere Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | $150.74M | $-85.63M | $-86.33M | $-65.82M | $-69.66M | - | $-75.97M | $-51.57M | $-35.64M | $-39.01M | $-53.87M | $-121.62M | $-22.55M | $-26.07M | $808.00K | $-30.26M | $-36.49M | $-38.70M | $-40.98M |
| Avg Forecast | $-7.44M | $-21.86M | $-27.90M | $-40.77M | $-42.17M | $-48.45M | $-61.30M | $-59.48M | $-89.72M | $-82.49M | $-84.37M | $-54.07M | $-87.89M | $-35.57M | $-72.42M | $-49.16M | $-39.44M | $-32.34M | $-43.82M | $-27.35M | $-32.88M | $-39.44M | $-35.18M | $-42.98M | $-45.01M | $-58.01M | $-38.35M | $-34.99M |
| High Forecast | $-5.20M | $-15.29M | $-19.52M | $-28.52M | $-29.50M | $-38.90M | $-42.88M | $-47.58M | $-60.05M | $2.76B | $-59.01M | $-43.26M | $-61.48M | $-28.46M | $-72.42M | $-39.33M | $-31.55M | $-25.87M | $-35.06M | $-21.88M | $-25.73M | $-30.86M | $-27.52M | $-33.63M | $-35.22M | $-45.39M | $-30.00M | $-27.37M |
| Low Forecast | $-10.00M | $-29.38M | $-37.51M | $-54.81M | $-56.70M | $-66.20M | $-82.42M | $-71.38M | $-109.50M | $-2.23B | $-113.43M | $-64.89M | $-118.16M | $-42.69M | $-72.42M | $-58.99M | $-47.33M | $-38.81M | $-52.59M | $-32.82M | $-45.32M | $-54.35M | $-48.48M | $-59.23M | $-62.03M | $-79.95M | $-52.85M | $-48.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.83% | 1.01% | 1.60% | 0.75% | 1.96% | - | 1.55% | 1.31% | 1.10% | 0.89% | 1.97% | 3.70% | 0.57% | 0.74% | -0.02% | 0.67% | 0.63% | 1.01% | 1.17% |
Travere Therapeutics's average Quarter net income forecast for Dec 23 is $-89.72M, with a range of $-109.50M to $-60.05M. TVTX's average Quarter net income forecast represents a -159.52% decrease compared to the company's last Quarter net income of $150.74M (Sep 23).
Travere Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | $67.80M | $74.04M | $72.25M | $62.92M | $57.52M | - | $46.79M | $42.08M | $36.06M | $34.97M | $36.78M | $35.74M | $31.95M | $34.97M | $33.14M | $27.53M | $29.78M | $38.97M | $32.67M |
| Avg Forecast | $102.82M | $87.11M | $79.24M | $64.88M | $63.22M | $57.36M | $47.24M | $36.63M | $39.08M | $53.74M | $50.20M | $33.30M | $49.69M | $36.00M | $46.52M | $30.27M | $32.17M | $32.73M | $39.28M | $18.67M | $48.42M | $44.84M | $44.61M | $40.70M | $43.14M | $42.45M | $40.31M | $38.81M |
| High Forecast | $130.07M | $110.20M | $100.24M | $82.07M | $79.97M | $73.80M | $59.76M | $43.96M | $41.49M | $123.69M | $63.51M | $39.96M | $62.86M | $43.20M | $46.52M | $36.33M | $38.61M | $39.27M | $47.13M | $22.41M | $62.51M | $57.88M | $57.58M | $52.54M | $55.68M | $54.80M | $52.04M | $50.10M |
| Low Forecast | $79.06M | $66.98M | $60.92M | $49.88M | $48.61M | $45.32M | $36.32M | $29.31M | $36.84M | $14.22M | $38.60M | $26.64M | $38.21M | $28.80M | $46.52M | $24.22M | $25.74M | $26.18M | $31.42M | $14.94M | $40.32M | $37.33M | $37.14M | $33.89M | $35.92M | $35.35M | $33.56M | $32.31M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.26% | 1.47% | 2.17% | 1.27% | 1.60% | - | 1.55% | 1.31% | 1.10% | 0.89% | 1.97% | 0.74% | 0.71% | 0.78% | 0.81% | 0.64% | 0.70% | 0.97% | 0.84% |
Travere Therapeutics's average Quarter SG&A projection for Dec 23 is $39.08M, based on 8 Wall Street analysts, with a range of $36.84M to $41.49M. The forecast indicates a -42.36% fall compared to TVTX last annual SG&A of $67.80M (Sep 23).
Travere Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 8 | 8 | 8 | 9 | 10 | 9 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | $1.98 | $-0.00 | $-1.27 | $-1.03 | $-1.09 | - | $-1.20 | $-0.84 | $-0.59 | $-0.64 | $-0.96 | $-2.37 | $-0.44 | $-0.58 | $0.02 | $-0.70 | $-0.85 | $-0.92 | $-0.99 |
| Avg Forecast | $-0.10 | $-0.28 | $-0.36 | $-0.53 | $-0.54 | $-0.63 | $-0.79 | $-0.96 | $-1.16 | $-1.06 | $-1.09 | $-1.20 | $-1.13 | $-0.95 | $-0.94 | $-0.87 | $-0.74 | $-0.56 | $-0.68 | $-0.52 | $-0.43 | $-0.52 | $-0.46 | $-0.56 | $-0.59 | $-0.76 | $-0.50 | $-0.46 |
| High Forecast | $-0.07 | $-0.20 | $-0.25 | $-0.37 | $-0.38 | $-0.50 | $-0.55 | $-0.67 | $-0.77 | $35.55 | $-0.76 | $-0.84 | $-0.79 | $-0.66 | $-0.94 | $-0.68 | $-0.58 | $-0.44 | $-0.53 | $-0.41 | $-0.34 | $-0.40 | $-0.36 | $-0.44 | $-0.46 | $-0.59 | $-0.39 | $-0.36 |
| Low Forecast | $-0.13 | $-0.38 | $-0.48 | $-0.71 | $-0.73 | $-0.85 | $-1.06 | $-1.29 | $-1.41 | $-28.74 | $-1.46 | $-1.61 | $-1.52 | $-1.27 | $-0.94 | $-1.20 | $-1.01 | $-0.77 | $-0.94 | $-0.72 | $-0.59 | $-0.71 | $-0.63 | $-0.77 | $-0.81 | $-1.05 | $-0.69 | $-0.63 |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.86% | 0.00% | 1.06% | 0.91% | 1.15% | - | 1.38% | 1.14% | 1.05% | 0.94% | 1.84% | 5.51% | 0.85% | 1.26% | -0.04% | 1.19% | 1.12% | 1.83% | 2.16% |
According to 8 Wall Street analysts, Travere Therapeutics's projected average Quarter EPS for Dec 23 is $-1.16, with a low estimate of $-1.41 and a high estimate of $-0.77. This represents a -158.47% decrease compared to TVTX previous annual EPS of $1.98 (Sep 23).
Travere Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| COGT | Cogent Biosciences | $10.63 | $18.50 | 74.04% | Buy |
| TVTX | Travere Therapeutics | $13.48 | $21.60 | 60.24% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| LEGN | Legend Biotech | $50.31 | $78.78 | 56.59% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
TVTX Forecast FAQ
Is Travere Therapeutics a good buy?
Yes, according to 11 Wall Street analysts, Travere Therapeutics (TVTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 81.82% of TVTX's total ratings.
What is TVTX's price target?
Travere Therapeutics (TVTX) average price target is $21.6 with a range of $12 to $28, implying a 60.24% from its last price of $13.48. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Travere Therapeutics stock go up soon?
According to Wall Street analysts' prediction for TVTX stock, the company can go up by 60.24% (from the last price of $13.48 to the average price target of $21.6), up by 107.72% based on the highest stock price target, and down by -10.98% based on the lowest stock price target.
Can Travere Therapeutics stock reach $20?
TVTX's average twelve months analyst stock price target of $21.6 supports the claim that Travere Therapeutics can reach $20 in the near future.
What is Travere Therapeutics's current price target trend?
3 Wall Street analysts forecast a $20 price target for Travere Therapeutics (TVTX) this month, up 48.37% from its last price of $13.48. Compared to the last 3 and 12 months, the average price target increased by 48.37% and increased by 44.66%, respectively.
What are Travere Therapeutics's analysts' financial forecasts?
Travere Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $222.5M (high $282.78M, low $172.37M), average EBITDA is $-171M (high $-134M, low $-214M), average net income is $-211M (high $-159M, low $-277M), average SG&A $204.45M (high $257.48M, low $159.55M), and average EPS is $-2.919 (high $-2.106, low $-3.938). TVTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $356.4M (high $450.84M, low $274.02M), average EBITDA is $-239M (high $-184M, low $-302M), average net income is $-97.96M (high $-68.524M, low $-132M), average SG&A $334.06M (high $422.58M, low $256.84M), and average EPS is $-1.264 (high $-0.884, low $-1.699).
Did the TVTX's actual financial results beat the analysts' financial forecasts?
Based on Travere Therapeutics's last annual report (Dec 2022), the company's revenue was $212.02M, beating the average analysts forecast of $208.96M by 1.47%. Apple's EBITDA was $-244M, beating the average prediction of $-134M by 82.33%. The company's net income was $-278M, beating the average estimation of $-245M by 13.65%. Apple's SG&A was $220.21M, beating the average forecast of $162.48M by 35.52%. Lastly, the company's EPS was $-4.37, beating the average prediction of $-3.891 by 12.32%. In terms of the last quarterly report (Sep 2023), Travere Therapeutics's revenue was $37.1M, missing the average analysts' forecast of $57.33M by -35.30%. The company's EBITDA was $-89.241M, beating the average prediction of $-38.396M by 132.42%. Travere Therapeutics's net income was $150.74M, missing the average estimation of $-82.494M by -282.72%. The company's SG&A was $67.8M, beating the average forecast of $53.74M by 26.16%. Lastly, the company's EPS was $1.98, missing the average prediction of $-1.064 by -286.01%